Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, has announced a capital increase of a nominal amount of €597,897 by means of the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares following the approval by the US FDA (Food and Drug Administration) of the new drug application in the US for ZERVIATE (cetirizine ophthalmic solution) 0.24% (see the Company’s press release of 31 May 2017), in order to provide former Aciex shareholders with the Nicox shares due to them in respect of their category A-1 Contingent Value Rights (see the document dated 30 September 2014 registered with the Autorité des Marchés Financiers under no. E. 14-060 available on Nicox’ website). These new shares are issued at their nominal value and fully paid up, with the amount deducted from the acquisition premium account.
The impact of the issue on the stake held in the Company’s share capital and the share of equity as at 31 December 2016 of a shareholder holding 1% of share capital at the time of the issue (calculations based on a non-diluted basis and a fully diluted basis, i.e. taking into account the issuance of a maximum of 1, 578,822 new shares following (i) the exercise of all the Contingent Value Rights and stock options, (ii) the definitive acquisition of all free shares outstanding and ), (iii) the issue of new shares to result from Categories B and C Contingent Value Rights granted to the former shareholders of Aciex is as follows:.
Total number of Nicox shares outstanding
Share of equity
Before issue of 597,897 new shares
25 071 441
€1 045 490,0
After issue of 597,897 new shares (non-diluted basis)
25 669 338
€1 080 628,4
After issue of 597,897 new shares and of 1,578,822 new shares resulting from outstanding share rights (fully diluted basis)
27 248 160
€1 102 069,2